Prespecified Analysis of ATHOS-3 Indicates Survival Benefit in LJPC-501-Treated Patients with Relatively Low Angiotensin II State Analysis

Analysis to Be Presented in Oral Session at the 30th Annual Congress of The European Society of Intensive Care Medicine SAN DIEGO, CA – September 20, 2017 – La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla) today announced an abstract entitled “Baseline angiotensin levels and ACE effects in patients with vasodilatory shock […]

La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501

La Jolla Pharmaceutical Company Announces U.S. FDA Acceptance of New Drug Application for LJPC-501 – Priority Review Granted – SAN DIEGO–(BUSINESS WIRE)–Aug. 28, 2017– La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla) today announced that the U.S. Food and Drug Administration (FDA) has accepted for review the Company’s New Drug Application (NDA) for the investigational drug LJPC-501 […]

La Jolla Pharmaceutical Company Announces Launch of Expanded Access Program for LJPC-501

SAN DIEGO–(BUSINESS WIRE)–Aug. 8, 2017– La Jolla Pharmaceutical Company (NASDAQ: LJPC) (the Company or La Jolla), today announced that the Company has initiated an expanded access program (EAP) in the United States to provide its investigational drug, LJPC-501 (angiotensin II), to patients with vasodilatory or distributive shock who cannot achieve target mean arterial pressure (MAP) despite adequate fluid resuscitation […]

Results of ATHOS‑3 Phase 3 Study of LJPC-501 Published in The New England Journal of Medicine

SAN DIEGO–(BUSINESS WIRE)–May 21, 2017– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (La Jolla) today announced that results of the ATHOS-3 (Angiotensin II for the Treatment of High-OutputShock) Phase 3 study of LJPC-501 (angiotensin II) have been published online by The New England Journal of Medicine (NEJM). The article, entitled “Angiotensin II for the Treatment of […]

La Jolla Pharmaceutical Company Announces Positive Top-Line Results from ATHOS-3 Phase 3 Study of LJPC-501

— Primary efficacy endpoint analysis highly statistically significant (p<0.00001) — Trend toward longer survival observed — New Drug Application planned for second half of 2017 — Company to host conference call and webcast at 8:30 a.m. EST on Monday, Feb. 27, 2017 SAN DIEGO–(BUSINESS WIRE)–Feb. 27, 2017– La Jolla Pharmaceutical Company (Nasdaq: LJPC) (La Jolla), […]